BCL2L12 Protein, Human, Recombinant (GST)

一键复制产品信息

SPR兼容缓冲液

BCL2L12 Protein, Human, Recombinant (GST)

产品编号 TMPY-03748

BCL2-like 12 (BCL2L12 ) is a new member of the apoptosis-related BCL2 gene family, members of which are implicated in various malignancies. The mRNA expression of BCL2L12 may constitute a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma. BCL2L12 is a recently identified gene belonging to the BCL2 family, members of which are implicated in hematologic malignancies, including chronic lymphocytic leukemia (CLL). BCL2L12 can be considered as a new independent prognostic and chemotherapy response marker in AML. BCL2L12 mRNA expression may serve as a potential prognostic biomarker in tongue and/or larynx SCC, which principally constitute the great majority of HNSCC cases worldwide. BCL2L12 mRNA expression is a favorable prognostic marker of DFS for BC patients, suggesting its possible application as a novel prognostic indicator of this malignancy.

BCL2L12 Protein, Human, Recombinant (GST)

一键复制产品信息

SPR兼容缓冲液

产品编号 TMPY-03748

规格	价格	库存
5 μg	¥ 493	6-8日内发货
10 μg	¥ 790	6-8日内发货
20 μg	¥ 1,330	5日内发货
50 μg	¥ 2,580	5日内发货
100 μg	¥ 5,170	5日内发货

大包装 & 定制

加入购物车

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

实验操作小课堂

常见问题解答

资源下载

重组蛋白用户指南

产品信息

生物活性	Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
产品描述	BCL2-like 12 (BCL2L12 ) is a new member of the apoptosis-related BCL2 gene family, members of which are implicated in various malignancies. The mRNA expression of BCL2L12 may constitute a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma. BCL2L12 is a recently identified gene belonging to the BCL2 family, members of which are implicated in hematologic malignancies, including chronic lymphocytic leukemia (CLL). BCL2L12 can be considered as a new independent prognostic and chemotherapy response marker in AML. BCL2L12 mRNA expression may serve as a potential prognostic biomarker in tongue and/or larynx SCC, which principally constitute the great majority of HNSCC cases worldwide. BCL2L12 mRNA expression is a favorable prognostic marker of DFS for BC patients, suggesting its possible application as a novel prognostic indicator of this malignancy.
种属	Human
表达系统	E. coli
标签	N-GST
蛋白编号	Q9HB09-1
别名	BCL2-like 12 (proline rich)
蛋白构建	A DNA sequence encoding the human BCL2L12 (Q9HB09-1) (Pro147-Lys227) was fused with the GST tag at the N-terminus. Predicted N terminal: Met
蛋白纯度	> 95 % as determined by SDS-PAGE
分子量	36 kDa (predicted); 33 kDa (reducing conditions)
内毒素	Please contact us for more information.
蛋白性状	Lyophilized powder
缓冲液	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 8.0.Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
复溶方法	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
存储	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice.
研究背景	BCL2-like 12 (BCL2L12 ) is a new member of the apoptosis-related BCL2 gene family, members of which are implicated in various malignancies. The mRNA expression of BCL2L12 may constitute a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma. BCL2L12 is a recently identified gene belonging to the BCL2 family, members of which are implicated in hematologic malignancies, including chronic lymphocytic leukemia (CLL). BCL2L12 can be considered as a new independent prognostic and chemotherapy response marker in AML. BCL2L12 mRNA expression may serve as a potential prognostic biomarker in tongue and/or larynx SCC, which principally constitute the great majority of HNSCC cases worldwide. BCL2L12 mRNA expression is a favorable prognostic marker of DFS for BC patients, suggesting its possible application as a novel prognostic indicator of this malignancy.